| Bioactivity | Volagidemab is an antagonistic glucagon receptor (GCGR) monoclonal antibody (mAb). Volagidemab can be used in the research of type 1 diabetes (T1D)[1][2]. |
| In Vivo | Volagidemab (5 mg/kg，皮下注射) 在四氧嘧啶诱导的糖尿病小鼠中抑制 1 型糖尿病表型[2]。 Animal Model: |
| Name | Volagidemab |
| CAS | 1233956-13-2 |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Pettus J, et al. Glucagon receptor antagonist volagidemab in type 1 diabetes: a 12-week, randomized, double-blind, phase 2 trial. Nat Med. 2022 Oct;28(10):2092-2099. [2]. Wang MY, et al. Glucagon receptor antibody completely suppresses type 1 diabetes phenotype without insulin by disrupting a novel diabetogenic pathway. Proc Natl Acad Sci U S A. 2015 Feb 24;112(8):2503-8. |